GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Iterum Therapeutics PLC (NAS:ITRM) » Definitions » Total Revenue Growth Rate (Future 3Y To 5Y Est)

Iterum Therapeutics (Iterum Therapeutics) Total Revenue Growth Rate (Future 3Y To 5Y Est) : N/A (As of May. 23, 2024)


View and export this data going back to 2018. Start your Free Trial

What is Iterum Therapeutics Total Revenue Growth Rate (Future 3Y To 5Y Est)?

Total Revenue Growth Rate (Future 3Y To 5Y Est) is the average growth rate of total revenue estimates over a 3-year to 5-year period.

As of today, Iterum Therapeutics's Total Revenue Growth Rate (Future 3Y To 5Y Est) is N/A.

Competitive Comparison of Iterum Therapeutics's Total Revenue Growth Rate (Future 3Y To 5Y Est)

For the Biotechnology subindustry, Iterum Therapeutics's Total Revenue Growth Rate (Future 3Y To 5Y Est), along with its competitors' market caps and Total Revenue Growth Rate (Future 3Y To 5Y Est) data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Iterum Therapeutics's Total Revenue Growth Rate (Future 3Y To 5Y Est) Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Iterum Therapeutics's Total Revenue Growth Rate (Future 3Y To 5Y Est) distribution charts can be found below:

* The bar in red indicates where Iterum Therapeutics's Total Revenue Growth Rate (Future 3Y To 5Y Est) falls into.


Iterum Therapeutics  (NAS:ITRM) Total Revenue Growth Rate (Future 3Y To 5Y Est) Explanation

Total Revenue Growth Rate (Future 3Y To 5Y Est) is the growth rate of total revenue estimates over a 3-year to 5-year period. This data is provided directly by our trusted data vendors Refinitiv or Morningstar.

In situations where both vendors do not directly provide the growth rate data, we use the most recent annual revenue for the current year and estimated future revenue figures provided by the vendor to calculate the growth rate. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average total revenue estimates growth rate.

Iterum Therapeutics Total Revenue Growth Rate (Future 3Y To 5Y Est) Related Terms

Thank you for viewing the detailed overview of Iterum Therapeutics's Total Revenue Growth Rate (Future 3Y To 5Y Est) provided by GuruFocus.com. Please click on the following links to see related term pages.

Iterum Therapeutics (Iterum Therapeutics) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Iterum Therapeutics PLC (NAS:ITRM) » Definitions » Total Revenue Growth Rate (Future 3Y To 5Y Est)
Comparable Companies
OGEN BCEL CNSP VRPX BRTX VIRI INTI PCSA ENZN BCDA OCSE:NOVO B VRTX REGN ASX:CSL SGEN XKRX:207940 MRNA HKSE:02269 XBRU:ARGX BNTX
Traded in Other Exchanges
N/A
Address
Fitzwilliam Court, 1st Floor, Leeson Close, Dublin, IRL, 2
Website
https://www.iterumtx.com
Iterum Therapeutics PLC is a clinical-stage pharmaceutical company. The company is engaged in developing and commercializing sulopenem to be the first and only oral and intravenous branded penem available globally. Its sulopenem program has the potential to offer a solution to the problem of antibiotic resistance and the toxicity limitations of existing agents. The company operates as a single business segment, which is the development and commercialization of innovative treatments for drug-resistant bacterial infections.
Executives
Michael W. Dunne officer: Chief Scientific Officer DURATA THERAPEUTICS, INC., 89 HEADQUARTERS PLAZA NORTH, 14TH FLOOR, MORRISTOWN NJ 07960
Fishman Corey N. director, officer: President & CEO DURATA THERAPEUTICS, INC., 89 HEADQUARTERS PLAZA NORTH, 14TH FLOOR, MORRISTOWN NJ 07960
Sailaja Puttagunta officer: Chief Medical Officer C/O BIOMX LTD., 7 PINHAS SAPIR ST., FLOOR 2, NESS ZIONA L3 7414002
Brenton Karl Ahrens director 2765 SAND HILL ROAD, MENLO PARK CA 94025
Judith M. Matthews officer: Chief Financial Officer 200 WEST MONROE ST., SUITE 1575, CHICAGO IL 60606
Beth Hecht director C/O NEOS THERAPEUTICS, INC., 2940 N. HIGHWAY 360, GRAND PRAIRIE TX 75050
Alexander J Denner 10 percent owner C/O SARISSA CAPITAL MANAGEMENT LP, 660 STEAMBOAT ROAD, 3RD FLOOR, GREENWICH CT 06830
Sarissa Capital Hawkeye Fund Lp 10 percent owner 660 STEAMBOAT ROAD, 3RD FLOOR, GREENWICH CT 06830
Sarissa Capital Catapult Fund Llc 10 percent owner 660 STEAMBOAT ROAD, 3RD FLOOR, GREENWICH CT 06830
Sarissa Capital Master Fund Ii Lp 10 percent owner C/O SARISSA CAPITAL MANAGEMENT LP, 660 STEAMBOAT ROAD, 3RD FLOOR, GREENWICH CT 06830
Sarissa Capital Offshore Master Fund Lp 10 percent owner C/O SARISSA CAPITAL MANAGEMENT, 660 STEAMBOAT ROAD 3RD FLOOR, GREENWICH CT 06830
Sarissa Capital Management Lp 10 percent owner 660 STEAMBOAT ROAD, GREENWICH CT 06830
Peter Kolchinsky 10 percent owner 200 BERKELEY STREET, 18TH FLOOR, BOSTON MA 02116
Ra Capital Management, L.p. 10 percent owner 200 BERKELEY STREET, 18TH FLOOR, BOSTON MA 02116
Ra Capital Healthcare Fund Lp 10 percent owner 200 BERKELEY STREET, 18TH FLOOR, BOSTON MA 02116